Nel ASA's Order Intake Becomes the Lone Bright Spot in a Quiet Stretch

Nel ASA's Q2 order intake surged 224% to 230M NOK, but revenue fell 12% and EBITDA was negative. Q3 results on Oct 21 will test recovery.

The Norwegian electrolyser maker has slipped into a news vacuum since its second-quarter report landed in mid-July, leaving investors to parse a mixed set of operational signals. Nel ASA's share price has drifted to around 0.1932 euros, hovering near its 50-day moving average and roughly 12 percent above the 52-week low of 0.1731 euros — yet still a painful 47 percent below the springtime peak of 0.3655 euros.

That gap between the stock's floor and ceiling captures the central tension: a business that keeps bleeding cash while showing flickers of a demand revival that has yet to translate into revenue growth.

The One Metric That Points Higher

Revenue from customer contracts came in at 153 million Norwegian kroner in the second quarter, down 12 percent year on year, while EBITDA sank to minus 155 million kroner — a figure that absorbed a 7.5 million US dollar legal settlement with Iwatani. On the surface, the numbers tell a story of contraction.

But buried in the same report is a figure that stands out: order intake jumped to 230 million kroner, a 224 percent surge from the prior-year period, with 96 percent of that coming from the PEM business. The order backlog sits at 1.2 billion kroner, and the company holds 1.3 billion kroner in cash.

That single spike is what separates the current situation from a straightforward deterioration. Whether it marks the beginning of a sustained recovery or a one-off windfall is now the question dominating how the market prices the equity.

A Calendar Date Looms

The next test arrives on 21 October, when Nel publishes its third-quarter results. If order intake holds near or above the 230 million kroner mark, the narrative shifts toward a company whose pipeline is finally filling — even if the income statement has yet to catch up. A sharp pullback, by contrast, would suggest the spring surge was an anomaly in a market where large projects land irregularly and can distort quarterly comparisons.

Until then, the stock looks set to trade sideways, with any news about new contracts or project milestones likely to move the price out of proportion to its fundamental weight.

No News, But a Move Anyway

Thursday's session illustrated exactly that dynamic. Nel shares climbed 3.5 percent to 0.1966 euros with no identifiable catalyst — no company announcement, no analyst action, nothing in the news flow to explain the advance. The move underscores how sensitive the stock remains to any whiff of hydrogen optimism, even in the absence of a concrete trigger.

Part of that sensitivity stems from the broader sector narrative. Market forecasts project the global fuel cell market expanding from 5.4 billion US dollars in 2025 to 13.1 billion US dollars by 2031, a compound annual growth rate of 17.3 percent. Such figures keep the long-term hydrogen story alive, though they do little to explain day-to-day moves in a company that operates primarily in electrolysis rather than fuel cells.

Structural Ambition Meets Operational Reality

Nel's strategic bet rests on the new pressurized alkaline electrolyser system, which entered commercial marketing roughly four months ago. The company has announced production ramp-up at Herøya, backed by a 135 million euro grant from the EU Innovation Fund covering up to 60 percent of project costs. Capacity there could eventually reach 4 gigawatts annually, with targeted cost reductions of 40 to 60 percent versus existing market solutions.

That combination — state-backed funding and ambitious technology goals — provides the bull case. The bear case is equally visible: a shrinking revenue base, persistent losses, and an order book that has yet to convert into profitable growth.

Adding to the backdrop is the pending departure of CEO Håkon Volldal, who will leave after a six-month notice period. The market has already digested that news, and it currently provides no fresh impetus in either direction.

A Stock Caught Between Hope and Evidence

For now, Nel trades in a waiting pattern. The order intake from the second quarter offers the only concrete reason for optimism, but as a leading indicator it lacks proof until it shows up in actual revenues. The third-quarter report will provide the first real evidence of whether the spring surge was a turning point or an isolated data point.

Until that day arrives, investors are left with a stock that reacts sharply to sector sentiment, moves on days when nothing happens, and remains far below the levels it reached when hydrogen enthusiasm ran hotter. The coming weeks will determine whether the order book becomes the foundation of a recovery story — or just another footnote in a prolonged downturn.